PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32619893-4	2020	CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy.	Cyclophosphamide	126-142	keratin 20	Homo sapiens	206-210	
27084027-1	2016	Rituximab is a chimeric anti-CD20 monoclonal antibody that is used as an immunosuppressive agent in cyclophosphamide refractory lupus nephritis to induce remission.	Cyclophosphamide	100-116	keratin 20	Homo sapiens	29-33	
30867701-7	2019	Also, after rituximab treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly lower than those in cyclophosphamide group (P<0.05), and platelet count was higher than that in cyclophosphamide group (P<0.05).	Cyclophosphamide	207-223	keratin 20	Homo sapiens	58-62	
30235659-10	2018	When the first-line therapy of cyclophosphamide combined with prednisone is not enough to eradicate the inhibitor, especially for a higher inhibitor titer, anti-CD20 monoclonal antibody could play an important role.	Cyclophosphamide	31-47	keratin 20	Homo sapiens	161-165	
27454143-7	2017	In the present study, the role of oral cyclophosphamide (100 mg per day for 15 consecutive days, every 30 for a total of six cycles) associated with anti-CD20 monoclonal antibody has been evaluated in 30 newly diagnosed SMZL patients, not fit for splenectomy or more toxic chemotherapic regimens.	Cyclophosphamide	39-55	keratin 20	Homo sapiens	154-158	
21339937-5	2010	On the basis of these findings, the US Food and Drug Administration (FDA) recently approved rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed/refractory or previously untreated CD20-postive CLL.	Cyclophosphamide	138-154	keratin 20	Homo sapiens	234-238	
26489498-2	2015	Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine and cyclophosphamide.	Cyclophosphamide	281-297	keratin 20	Homo sapiens	37-41	
22721383-6	2012	After combining with either adriamycin or cyclophosphamide, the binding capacity of R to the CD20 antigen was equivalent to controls, and no molecular changes in adriamycin and cyclophosphamide were detected after combination with R. Twenty-one cases of DLBCL were treated safely with concurrent administration of R and CHOP.	Cyclophosphamide	42-58	keratin 20	Homo sapiens	93-97	
22249209-8	2012	Of the 105 patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy, those who were CD20 negative (FCM) showed significantly inferior overall (hazard ratios (HR): 6.79, 95% CI: 1.32-34.96, p = 0.04) and progression-free survival (HR: 7.3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal.	Cyclophosphamide	48-64	keratin 20	Homo sapiens	133-137	
21842694-6	2011	Because CD20 immunostaining was positive, the patient received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) without any signs of major toxicity.	Cyclophosphamide	90-106	keratin 20	Homo sapiens	8-12	
20660823-1	2010	PURPOSE: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone).	Cyclophosphamide	262-278	keratin 20	Homo sapiens	34-38	
18537979-6	2008	The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.	Cyclophosphamide	78-94	keratin 20	Homo sapiens	36-40	
15170171-4	2004	Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood.	Cyclophosphamide	148-164	keratin 20	Homo sapiens	35-39	
17661091-0	2007	Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.	Cyclophosphamide	104-120	keratin 20	Homo sapiens	88-92	
17354532-3	2007	Among novel developments based on biologicals, the anti-CD20 monoclonal antibody rituximab (anti-B cells) appears encouraging in open studies, in association or not with cyclophosphamide, and is generally well tolerated.	Cyclophosphamide	170-186	keratin 20	Homo sapiens	56-60	
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	Cyclophosphamide	39-55	keratin 20	Homo sapiens	172-176	
12902896-4	2003	We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.	Cyclophosphamide	63-79	keratin 20	Homo sapiens	157-162	
12447847-5	2002	The anti-CD20 monoclonal antibody rituximab also is effective in treating CLL and is being evaluated in combination with chemotherapeutic agents (cyclophosphamide) and fludarabine.	Cyclophosphamide	146-162	keratin 20	Homo sapiens	9-13	
12141952-8	2002	The triple combination of fludarabine/cyclophosphamide/mitoxantrone and fludarabine combinations with anti-CD20 (rituximab) or anti-CD52 (Campath-1H) antibody, might be even be more promising, since a relevant number of complete molecular remissions are achieved with these drugs.	Cyclophosphamide	38-54	keratin 20	Homo sapiens	107-111	
7538976-5	1995	In the surviving breast cancer patients there was a significant decrease in the percentage of non-B lymphocyte HLA-DR+ (CD20-HLA-DR+) cells following cyclophosphamide treatment.	Cyclophosphamide	150-166	keratin 20	Homo sapiens	120-124	
7538976-7	1995	Breast cancer patients who showed a greater than median decrease in CD20-HLA-DR+ lymphocytes following cyclophosphamide treatment had a survival advantage over patients who had less than the median decrease in the percent CD20-HLA-DR+ lymphocytes.	Cyclophosphamide	103-119	keratin 20	Homo sapiens	68-72	
7538976-7	1995	Breast cancer patients who showed a greater than median decrease in CD20-HLA-DR+ lymphocytes following cyclophosphamide treatment had a survival advantage over patients who had less than the median decrease in the percent CD20-HLA-DR+ lymphocytes.	Cyclophosphamide	103-119	keratin 20	Homo sapiens	222-226